Eikon Therapeutics, Inc. (EIKN) Stock Statistics & Valuation Metrics
Total Valuation
Eikon Therapeutics, Inc. has a market cap or net worth of $346.11M. The enterprise value is $427.28M.
- Market Cap
- $346.11M
- Enterprise Value
- $427.28M
Share Statistics
Eikon Therapeutics, Inc. has 54,165,030 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 54,165,030
- Owned by Insiders
- 22.48%
- Owned by Institutions
- 23.82%
Financial Efficiency
Eikon Therapeutics, Inc.’s return on equity (ROE) is 0.37 and return on invested capital (ROIC) is -61.65%.
- Return on Equity (ROE)
- 0.37
- Return on Assets (ROA)
- -0.55
- Return on Invested Capital (ROIC)
- -61.65%
- Return on Capital Employed (ROCE)
- -0.63
- Revenue Per Employee
- 0
- Profits Per Employee
- -844.40K
- Employee Count
- 384
- Asset Turnover
- 0.00
- Inventory Turnover
- 0.00
Valuation Ratios
The current PE Ratio of Eikon Therapeutics, Inc. is -1.26. Eikon Therapeutics, Inc.’s PEG ratio is 0.01.
- PE Ratio
- -1.26
- PS Ratio
- 0.00
- PB Ratio
- 0.68
- Price to FCF
- -1.22
- Price to Operating Cash Flow
- -1.24
- PEG Ratio
- 0.01
Income Statement
In the last 12 months, Eikon Therapeutics, Inc. had revenue of 0 and earned -324.25M in profits. Earnings per share was -6.16.
- Revenue
- 0
- Gross Profit
- -24.18M
- Operating Income
- -338.94M
- Pretax Income
- -324.25M
- Net Income
- -324.25M
- EBITDA
- -299.24M
- Earnings Per Share (EPS)
- -6.16
Cash Flow
In the last 12 months, operating cash flow was -256.02M and capital expenditures -3.18M, giving a free cash flow of -259.20M billion.
- Operating Cash Flow
- -256.02M
- Free Cash Flow
- -259.20M
- Free Cash Flow per Share
- -4.79
Dividends & Yields
Eikon Therapeutics, Inc. pays an annual dividend of ―, resulting in a dividend yield of ―
- Dividend Per Share
- ―
- Dividend Yield
- ―
- Payout Ratio
- N/A
- Free Cash Flow Yield
- -81.85%
- Earnings Yield
- -101.71%
Stock Price Statistics
- Beta
- 2.02
- 52-Week Price Change
- -61.07%
- 50-Day Moving Average
- 8.33
- 200-Day Moving Average
- 10.41
- Relative Strength Index (RSI)
- 39.29
- Average Volume (3m)
- 579.25K
Important Dates
Eikon Therapeutics, Inc. upcoming earnings date is ―, After Close (Confirmed).
- Last Earnings Date
- Aug 13, 2026
- Next Earnings Date
- ―
- Ex-Dividend Date
- ―
Financial Position
Eikon Therapeutics, Inc. as a current ratio of 6.34, with Debt / Equity ratio of -29.27%
- Current Ratio
- 6.34
- Quick Ratio
- 6.34
- Debt to Market Cap
- 0.00
- Net Debt to EBITDA
- -0.51
- Interest Coverage Ratio
- -404.95
Taxes
In the past 12 months, Eikon Therapeutics, Inc. has paid 0 in taxes.
- Income Tax
- 0
- Effective Tax Rate
- 0.00
Enterprise Valuation
Eikon Therapeutics, Inc. EV to EBITDA ratio is -1.43, with an EV/FCF ratio of -1.64.
- EV to Sales
- 0.00
- EV to EBITDA
- -1.43
- EV to Free Cash Flow
- -1.64
- EV to Operating Cash Flow
- -1.66
Balance Sheet
Eikon Therapeutics, Inc. has $531.58M in cash and marketable securities with $252.22M in debt, giving a net cash position of $279.36M billion.
- Cash & Marketable Securities
- $531.58M
- Total Debt
- $252.22M
- Net Cash
- $279.36M
- Net Cash Per Share
- $5.16
- Tangible Book Value Per Share
- $8.62
Margins
Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
- Gross Margin
- 0.00%
- Operating Margin
- 0.00%
- Pretax Margin
- 0.00%
- Net Profit Margin
- 0.00%
- EBITDA Margin
- 0.00%
- EBIT Margin
- 0.00%
Analyst Forecast
The average price target for Eikon Therapeutics, Inc. is $29.00, which is 11.43% higher than the current price. The consensus rating is Strong Buy
- Price Target
- $29.00
- Price Target Upside
- 396.58% Upside
- Analyst Consensus
- Strong Buy
- Analyst Count
- 4
- Revenue Growth Forecast
- ―
- EPS Growth Forecast
- ―
Scores
- Smart Score
- 9
- AI Score
- ―
